BRPI0506909A - derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central - Google Patents

derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central

Info

Publication number
BRPI0506909A
BRPI0506909A BRPI0506909-2A BRPI0506909A BRPI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A
Authority
BR
Brazil
Prior art keywords
benzo
derivatives
dihydro
treatment
nervous system
Prior art date
Application number
BRPI0506909-2A
Other languages
English (en)
Inventor
Meng Sui
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0506909A publication Critical patent/BRPI0506909A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE 1-BENZIL-5-PIPERAZIN-1-IL-3,4DIIDRO-1H-QUINAZOLIN-2-ONA E OS RESPECTIVOS DERIVADOS DE 1H-BENZO (1,2,6) TIADIAZINA-2,2-DIóXIDO E 1,4-DIIDRO-BENZO (D) (1,3)OXAZIN-2-ONA COMO MODULADORES DO RECEPTOR DE 5 HIDROXITRIPTAMINA (5-HT) PARA O TRATAMENTO DE DOENçAS DO SISTEMA NERVOSO CENTRAL. A presente invenção refere-se a compostos de quinazolina substituídos de fórmula (l) ou um sal farmaceuticamente aceitável desse, em que Y é C ou S; m é 1 quando Y é C e m é 2 quando Y é S; n é 1 ou 2; p é de 0 a 3; q é de 1 a 3; Z é -(CR~ a~ CR~ b~)r~- ou -SO~ 2~- em que r é de 0 a 2 e cada de R¬ a¬ e R¬ b¬ é independentemente hidrogênio ou alquila; X é CH ou N; R¬ 2¬ é arila opcionalmente substituída ou heteroarila opcionalmente substituída; preferivelmente R¬ 2¬ é arila, e mais preferivelmente fenila opcionalmente substituída por um ou mais trifluorometila, halo, ciano, C~ 1~-C~ 6~ alquila ou C~1-C~ 6~ alcóxi; A é -NR~ 3~- ou -O- em que R¬ 3¬ é: hidrogênio, alquila, acila, amidoalquila, hidroxialquila, ou alcoxialquila, os outros substituintes são definidos nas reivindicações. Os compostos são moduladores do receptor 5-hidroxitriptamina e são úteis para o tratamento de doencas do sistema nervoso central tais como psicose, esquizofrenia, depressões maníacas, distúrbios neurológicos, distúrbios de memória de distúrbio de déficit de atenção, doença de parkinson, esclerose lateral amiotrófica, doença de alzheimer, distúrbios de ingestãode alimentos, e doença de Huntington.
BRPI0506909-2A 2004-01-16 2005-01-07 derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central BRPI0506909A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53708004P 2004-01-16 2004-01-16
PCT/EP2005/000095 WO2005067933A1 (en) 2004-01-16 2005-01-07 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system

Publications (1)

Publication Number Publication Date
BRPI0506909A true BRPI0506909A (pt) 2007-05-29

Family

ID=34794441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506909-2A BRPI0506909A (pt) 2004-01-16 2005-01-07 derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central

Country Status (19)

Country Link
US (2) US7196087B2 (pt)
EP (1) EP1708713B1 (pt)
JP (1) JP4533391B2 (pt)
KR (1) KR100843053B1 (pt)
CN (1) CN1909909B (pt)
AR (1) AR047958A1 (pt)
AT (1) ATE388712T1 (pt)
AU (1) AU2005205016B2 (pt)
BR (1) BRPI0506909A (pt)
CA (1) CA2552681A1 (pt)
CO (1) CO5700763A2 (pt)
DE (1) DE602005005298T2 (pt)
ES (1) ES2302174T3 (pt)
IL (1) IL176631A0 (pt)
NO (1) NO20062791L (pt)
RU (1) RU2006129464A (pt)
TW (1) TW200530222A (pt)
WO (1) WO2005067933A1 (pt)
ZA (1) ZA200605434B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
CN101263136A (zh) * 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
NZ575426A (en) * 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
US7718652B2 (en) 2006-12-12 2010-05-18 Wyeth Llc Substituted benzothiadiazinedioxide derivatives and methods of their use
BRPI0822462A2 (pt) * 2008-06-20 2015-10-13 Rottapharm Spa derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.
EP2328881A1 (en) * 2008-09-08 2011-06-08 F. Hoffmann-La Roche AG 5-substituted benzoxazines
EP2592083A4 (en) 2010-05-21 2014-01-22 Shenzhen Salubris Pharm Co Ltd CONDENSED CHINAZOLINE DERIVATIVES AND THEIR USES
US10858368B2 (en) * 2016-11-15 2020-12-08 Temple University—Of the Commonwealth System of Higher Education Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体
CN114929688B (zh) * 2019-10-21 2024-11-01 阿莱瑞恩公司 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642791A (en) * 1969-08-13 1972-02-15 Sandoz Ag Morpholino-1-substituted-2(1h)-quinazolinones
JPS5271483A (en) * 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CN1015459B (zh) * 1985-06-06 1992-02-12 田边制药株式会社 喹唑啉酮化合物的制备方法
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
AU6423298A (en) 1997-03-26 1998-10-20 Sumitomo Pharmaceuticals Company, Limited 4-arylmethylene-1,4-dihydro-2h-azine derivatives
SI1028950T1 (en) 1997-10-28 2003-08-31 Warner-Lambert Company Llc 7-substituted quinazolin-2,4-diones useful as antibacterial agents
WO1999037643A1 (en) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
ES2234683T3 (es) * 1999-11-05 2005-07-01 Smithkline Beecham Plc Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d.
WO2001037837A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
JP2004521892A (ja) * 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
US6998408B2 (en) * 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
GB0203804D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування

Also Published As

Publication number Publication date
ES2302174T3 (es) 2008-07-01
US20070149510A1 (en) 2007-06-28
AU2005205016B2 (en) 2010-07-15
CN1909909B (zh) 2010-12-15
DE602005005298T2 (de) 2009-03-12
IL176631A0 (en) 2006-10-31
RU2006129464A (ru) 2008-02-27
JP2007517826A (ja) 2007-07-05
CO5700763A2 (es) 2006-11-30
AU2005205016A1 (en) 2005-07-28
TW200530222A (en) 2005-09-16
JP4533391B2 (ja) 2010-09-01
AR047958A1 (es) 2006-03-15
EP1708713B1 (en) 2008-03-12
ZA200605434B (en) 2008-02-27
CN1909909A (zh) 2007-02-07
US7196087B2 (en) 2007-03-27
EP1708713A1 (en) 2006-10-11
ATE388712T1 (de) 2008-03-15
US7365063B2 (en) 2008-04-29
CA2552681A1 (en) 2005-07-28
DE602005005298D1 (de) 2008-04-24
US20050165001A1 (en) 2005-07-28
KR20060126720A (ko) 2006-12-08
NO20062791L (no) 2006-08-01
WO2005067933A1 (en) 2005-07-28
KR100843053B1 (ko) 2008-07-01

Similar Documents

Publication Publication Date Title
BRPI0816767B8 (pt) composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
BR112015021336A2 (pt) compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
NO20091478L (no) Aminometyl-4-imidazoler
JO3569B1 (ar) مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
NO20062791L (no) 1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdom
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
BR112012003916A2 (pt) derivados de pirrolidinas como antagonistas de receptores nk3
MX2009012734A (es) Derivados de azaciclilbenzamida como antagonistas de histamina-3.
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
TW200719894A (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2205 DE 09/04/2013.